Adcock Ingram Integrated Report 2018

Manufactured capital CLAYVILLE WADEVILLE All the South African manufacturing sites have been declared as national key points during the year. REALISING CAPITAL OUTCOMES Manufacturing facility: Manufacturing facility: CAPACITY PER ANNUM 28 million effervescent tablets 400 tonnes Effervescent granules and powders 12 million ℓ oral liquids PURPOSE A state-of-the-art highly-automated high-volume liquids facility and a powders and effervescent plant. BOOK VALUE R749 million (2017: R692 million) property, plant and equipment PURPOSE A tablet and capsule facility which is focussed amongst others, on the manufacturing of anti- retroviral medicines, and a liquids, creams and ointments facility. BOOK VALUE R224 million (2017: R181 million) property, plant and equipment ACCREDITATIONS South Africa (SAHPRA), Ghana (FDB), Malawi (PMPB), Kenya (PPB), Zimbabwe (MCAZ), and Ethiopia (FMHACA). CAPACITY UTILISATION 75% Effervescents & powders 70% Liquids PROGRESS DURING THE YEAR All good manufacturing practice (GMP) upgrades to the general plant packing facility (Phase I) were completed during the year and all lines are up and running. A design and costing for Phase II has been prepared. The construction of the ophthalmic facility is on track for completion in the last quarter of calendar 2019. CAPACITY PER ANNUM 6 million ℓ Oral liquids 500 tonnes Creams/Ointments 2 billion Tablets and capsules ACCREDITATIONS South Africa (SAHPRA), Ghana (FDB), Malawi (PMPB), Kenya (PPB), Zimbabwe (MCAZ), and Botswana (DRU). CAPACITY UTILISATION 80% Liquids, creams and ointments 60% Tablets and capsules PROGRESS DURING THE YEAR The second phase of the upgrade to the Liquids, Creams and Ointment facility was completed during the year and completion of the final phase is expected by early 2020 calendar year. ADCOCK INGRAM  Integrated Report 2018 32 SUSTAINABILITY